secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lucid Diagnostics Inc. (LUCD)
CIK:        0001799011
Form:       8-K
Filed at:   2023-01-18T23:59:59+00:00
Accession:  0001493152-23-001724
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lucid/PAVmed cut 20% workforce, delay studies, halt products to reduce cash burn 25%
--------------------------------------------------------------------------------

- Workforce reduction of ~20% and other cost cuts aimed at lowering quarterly cash burn by at least 25%.
- Delays completion of EsoGuard BE-2 study to H2 2023; pauses EsoCure Esophageal Ablation device development.
- Maintains ~40 sales staff and nurse practitioners; shifts focus to large institutional accounts and satellite LTC program.
- PAVmed indefinitely pauses CarpX, PortIO, NextFlo product development; suspends annual cash bonuses.
- Veris Health delays implantable physiologic monitor development to H2 2023; prioritizes Cancer Care Platform adoption.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799011/000149315223001724/0001493152-23-001724-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799011/000149315223001724/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-001724

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer